Skip to content
DraconiticResearch
Search Sources API
186,546 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A One-Year Single-Center Retrospective Study

  • Dane Ediger1
  • Raziye Tülümen Öztürk1
  • Aylin Arslan1
  • İsmail Emre Deniz2
  1. 1Department of Pulmonary Diseases, Division of Allergy and Immunology, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Türkiye
  2. 2Department of Biostatistics, Institute of Health Sciences, Bursa Uludag University, 16059 Bursa, Türkiye
Open at sourceDOICite

Abstract

Background/Objectives: Benralizumab is effective in severe eosinophilic asthma, but real-world evidence on response characteristics and outcomes after switching from other biologics remains limited. This study evaluated one-year clinical, laboratory, and functional outcomes and factors associated with response. Methods: This single-centre retrospective observational study included 53 adults with severe eosinophilic asthma who reached the week 16 assessment; 40 continued treatment and completed 12 months. Outcomes were assessed at baseline, week 16, and month 12. Results: At week 16, 40 patients (75.5%) were responders and 13 (24.5%) were non-responders. Among 12-month completers, exacerbations, asthma-related hospitalisations, and systemic corticosteroid courses decreased significantly. Asthma Control Test scores and pulmonary function improved significantly, while blood eosinophil counts decreased markedly. Responders were older and more frequently atopic than non-responders. Improvement did not differ significantly among biologic-naïve patients and those switched from omalizumab or mepolizumab. Five patients (12.5%) met the super-responder criteria. Conclusions: Among patients who completed 12 months, benralizumab treatment was associated with improved asthma control and pulmonary function and fewer exacerbations and systemic corticosteroid courses. Changes did not differ significantly according to previous biologic treatment.

Related

  1. Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study
    Melis Yağdıran, Kurtuluş Aksu
    BMC Pulmonary MedicinePeer-reviewedCC BYFull textPhysiologyDOAJ
  2. Beyond eosinophil depletion: long-term clinical trajectory and durability of response to benralizumab in patients with severe eosinophilic asthma and CRSwNP: an 18-month real-world study (the BANDOR study)
    Emanuele Bizzi, Alessandro Maria Marra, Giuseppina Manzotti +18
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textPhysiologyCrossrefEurope PMCPMCEurope PMC
  3. A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma
    Dennis Thomas, Vanessa M. McDonald, Gijo Thomas +21
    Clinical and Experimental AllergyPeer-reviewedCC BY-NC 4.0Full text1 citedPhysiologyPMC
  4. Clinical outcomes and total IgE changes with omalizumab and dupilumab in moderate-to-severe asthma: a retrospective real-world cohort study
    Yan Chen, Boyun Yang, Wo Yao +7
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Real-world effectiveness and clinical outcomes of biologic therapy in severe asthma: A single-center experience from the United Arab Emirates.
    Muhammed Anas Ayoob, Khulood Abdulla Salem Al Mazrooei, Najla Salem Ahmed Al Nahdi
    Annals of thoracic medicinePeer-reviewedCC BY-NC-NDFull textPhysiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ediger2026realworld,
  title = {{Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A One-Year Single-Center Retrospective Study}},
  author = {Dane Ediger and Raziye Tülümen Öztürk and Aylin Arslan and İsmail Emre Deniz},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218360},
  url = {https://www.mdpi.com/2077-0383/15/21/8360},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A One-Year Single-Center Retrospective Study
AU  - Dane Ediger
AU  - Raziye Tülümen Öztürk
AU  - Aylin Arslan
AU  - İsmail Emre Deniz
PY  - 2026
DA  - 2026/10/27
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218360
UR  - https://www.mdpi.com/2077-0383/15/21/8360
AB  - Background/Objectives: Benralizumab is effective in severe eosinophilic asthma, but real-world evidence on response characteristics and outcomes after switching from other biologics remains limited. This study evaluated one-year clinical, laboratory, and functional outcomes and factors associated with response. Methods: This single-centre retrospective observational study included 53 adults with severe eosinophilic asthma who reached the week 16 assessment; 40 continued treatment and completed 12 months. Outcomes were assessed at baseline, week 16, and month 12. Results: At week 16, 40 patients (75.5%) were responders and 13 (24.5%) were non-responders. Among 12-month completers, exacerbations, asthma-related hospitalisations, and systemic corticosteroid courses decreased significantly. Asthma Control Test scores and pulmonary function improved significantly, while blood eosinophil counts decreased markedly. Responders were older and more frequently atopic than non-responders. Improvement did not differ significantly among biologic-naïve patients and those switched from omalizumab or mepolizumab. Five patients (12.5%) met the super-responder criteria. Conclusions: Among patients who completed 12 months, benralizumab treatment was associated with improved asthma control and pulmonary function and fewer exacerbations and systemic corticosteroid courses. Changes did not differ significantly according to previous biologic treatment.
SN  - 2077-0383
ER  -